
Opinion|Videos|August 23, 2024
Risk Stratification in Prostate Cancer Patients
Medical oncologists explore risk stratification strategies for newly diagnosed patients with prostate cancer, emphasizing the significant role of the Gleason score in diagnosis and prognosis.
Advertisement
Episodes in this series

Video content above is prompted by the following question:
- How do you approach risk stratification in prostate cancer patients, specifically in those newly diagnosed? (Brian Richardson, MD)
- Do you rely on the Gleason score, specific biomarkers, or a combination?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Individualizing androgen pathway therapy in mCSPC
3
Testosterone deficiency: FAQs from the AUA guideline
4
Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer
5

















